glp 1 shortage GLP-1 Antagonists Increase Plan Drug Spend - What's Next Shortage of GLP-1 receptor agonists

Comparison with previous studies The SUSTAIN 9 (Semaglutide once weekly as add-on to SGLT-2i therapy in T2DM) and SURPASS-1 (Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist Tirzepatide in patients with type 2 diabetes) trials demonstrated that both SGLT2i and GLP-1RAs reduced HbA1c and body weight levels compared with placebo in patients with a history of medical treatment for diabetes ( Safety outcomes The SUSTAIN-9 trial demonstrated an association between SGLT2i use and genital and urinary tract infections ( Discrepancies in the SGLT2i or GLP-1RA type and dosage across studies may have influenced the results

Lower semaglutide doses did not impact dopamine responses We repeated the experiment by injecting lower doses of semaglutide (0.1 and 0.3 mg/kg)

p = 0.12

doi: 10.1055/s-0035-1555791